Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ivo M. Hennig"'
Autor:
Joanne Bayly, Bethany M Edwards, Nicola Peat, Geoffrey Warwick, Ivo M Hennig, Arvind Arora, Andrew Wilcock, Irene J Higginson, Matthew Maddocks
Publikováno v:
Pilot and Feasibility Studies, Vol 4, Iss 1, Pp 1-12 (2018)
Abstract Background Access to rehabilitation to prevent disability and optimise function is recommended for patients with cancer, including following cancer diagnosis. Models to integrate rehabilitation within oncology services as cancer treatment co
Externí odkaz:
https://doaj.org/article/d4f1278865544941a4e85bc2a879e955
Autor:
Atheer, Zgair, Jonathan Cm, Wong, Jong Bong, Lee, Jatin, Mistry, Olena, Sivak, Kishor M, Wasan, Ivo M, Hennig, David A, Barrett, Cris S, Constantinescu, Peter M, Fischer, Pavel, Gershkovich
Publikováno v:
American journal of translational research. 8(8)
There has been an escalating interest in the medicinal use of Cannabis sativa in recent years. Cannabis is often administered orally with fat-containing foods, or in lipid-based pharmaceutical preparations. However, the impact of lipids on the exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bd2f388a64fa457c417b73aba42ded55
https://pubmed.ncbi.nlm.nih.gov/27648135
https://pubmed.ncbi.nlm.nih.gov/27648135
Autor:
Christopher Bradley, S Michael Crawford, Julia Brown, Ivo M. Hennig, David Alan Anthoney, Alex J Szubert, Alan M. Melcher, Jay D. Naik, Matthew T. Seymour, David A. Jackson, Sarah Brown
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(20)
Purpose Options for single-agent fluoropyrimidine adjuvant therapy after bowel cancer resection include intravenous fluorouracil with leucovorin (FU/LV) or oral capecitabine. These treatments have similar efficacy but differ in convenience and toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ee8da1360ad3438e563ab8f2fda724
https://pubmed.ncbi.nlm.nih.gov/18612156
https://pubmed.ncbi.nlm.nih.gov/18612156
Autor:
Ivo M. Hennig, Chris Twelves
Publikováno v:
European journal of cancer (Oxford, England : 1990). 44(11)
The emergence of novel, effective but expensive biological therapies is significantly improving outcomes for many patients with cancer, but also substantially increasing treatment costs. Monoclonal antibodies with long half-lives have often been deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4dd413394df0aa68aeec8b146753a66
https://pubmed.ncbi.nlm.nih.gov/18515087
https://pubmed.ncbi.nlm.nih.gov/18515087